Inactive

The Centers for Disease Control and Prevention (CDC) intends to solicit and negotiate a non-competitive modification to contract number 75D30122C13386, awarded to Quest Diagnostics, Inc. on March 4, 2... The Centers for Disease Control and Prevention (CDC) intends to solicit and negotiate a non-competitive modification to contract number 75D30122C13386, awarded to Quest Diagnostics, Inc. on March 4, 2022. This notice is provided in accordance with FAR 5.203(a). This contract is part of CDC's Multistate Assessment of SARS-CoV-2 Seroprevalence in Commercial Laboratory Survey (MASS-C) Study. The purpose of the contract is to estimate the proportion of people that have been infected by or vaccinated for SARS-CoV-2 during the ongoing pandemic over time, nationally, and by geographic location and demographic subcategory through identification of excess, remnant, or residual blood specimens from remaining volumes of previously obtained blood specimens in commercial laboratories for non-COVID-19 diagnostic or antibody testing across all 50 states, the District of Columbia and Puerto Rico. This modification will increase the scope of the contract to access data from the Contractor's informatics team on de-identified antibody results from specimens already tested and collected by the Contractor under this contract regarding the number of seropositive results that were from individuals who have immunocompromising conditions. The scope increase involved in this modification does not involve any further collection or testing of specimens/assays, but a deeper look into the results the Contractor has already reported to CDC and identification of the specimens in those results that are associated with individuals who are also considered immunocompromised. CDC believes the Contractor is best suited to perform the additional work to produce results of assays performed for clinical testing which would best align with the current samples in terms of geographic catchment area, as well as population of people who were accessing clinical testing. Awarding an entirely new contract for this additional work would be expensive in both money and resources as the general specimen base has already been collected, tested, and reported via the existing contract. The authority permitting other than full and open competition is FAR 6.302-1, "Only one responsible source and no other supplies or servies will satisfy agency requirements." This notice of intent is not for competitive quotations. However, all quotations/responses received within fifteen (15) days of the issuance of this notice will be considered by the Government. A determination by the Government to compete this proposed contract action (modification) based upon teh responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to qst7@cdc.gov